legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

**Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right**

Bristol Myers Squibb and Mirati Therapeutics have entered into a definitive merger agreement under which Bristol Myers Squibb will acquire Mirati for $58.00 per share in cash, resulting in a total equity value of $4.8 billion. In addition, Mirati stockholders will receive one non-tradeable Contingent Value Right (CVR) for each Mirati share held, potentially worth $12.00 per share in cash, adding an additional $1.0 billion of value opportunity. This acquisition has been unanimously approved by both companies’ Boards of Directors.

The acquisition of Mirati, a commercial stage targeted oncology company, aligns well with Bristol Myers Squibb’s portfolio and innovative pipeline, and presents an attractive opportunity to expand its oncology franchise. The addition of Mirati’s assets, particularly KRAZATI (adagrasib), a best-in-class KRASG12C inhibitor approved by the U.S. FDA for the treatment of advanced non-small cell lung cancer, strengthens Bristol Myers Squibb’s commercial portfolio. KRAZATI is also being developed for first-line therapy in combination with a PD-1 inhibitor for patients with non-small cell lung cancer.

Mirati’s promising pipeline includes MRTX1719, a potential first-in-class and best-in-class selective PRMT5/MTA inhibitor, as well as a KRAS and KRAS enabling program featuring MRTX1133 and MRTX0902.

The acquisition of Mirati will significantly enhance Bristol Myers Squibb’s oncology pipeline and provide promising options for single agent development and combination strategies. This includes KRAZATI, which has demonstrated efficacy as a second- and third-line treatment for patients with colorectal cancer and has shown potential as a monotherapy for previously treated pancreatic ductal adenocarcinoma.

**How AI legalese decoder can help with the situation:**

The AI legalese decoder is an advanced technology that can help both Bristol Myers Squibb and Mirati Therapeutics navigate the legal complexities of their merger agreement. With its ability to quickly analyze and interpret legal documents, the AI legalese decoder can ensure that both parties fully understand the terms and conditions of the agreement.

Additionally, the AI legalese decoder can assist in streamlining the merger process by automating the review of legal contracts and identifying any potential issues or discrepancies. This can help save time and resources, allowing the companies to complete the merger more efficiently.

By utilizing the AI legalese decoder, Bristol Myers Squibb and Mirati Therapeutics can have greater confidence in the legal aspects of their merger, ensuring a smooth transition and successful integration of their assets and operations.

legal-document-to-plain-english-translator/”>Try Free Now: Legalese tool without registration

Find a LOCAL lawyer

Reference link